Explore innovative nutritional and microbial strategies for effectively treating acne, alopecia, and atopic dermatitis.

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could ...

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...

Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong. Jakafi is approved for use ...

Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $741 ...

Researchers recently identified five extrapulmonary treatable traits in asthma that are clinically relevant and have a clear ...

The third edition of ImmunoSkin underscored Almirall’s commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Findings seen through 76 weeks of treatment for adolescents taking 15- or 30mg doses for moderate to severe atopic dermatitis.